Molecular Partners Ag (MOLN) Other Operating Expenses (2024 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Other Operating Expenses of -$116.3 million for Q4 2025, down 479.19% year-on-year from $30.7 million in Q4 2024, and down 9301382358.91% on a QoQ basis from $1.25 in Q3 2025.
Molecular Partners Ag (MOLN) Other Operating Expenses (2024 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other Operating Expenses for 2 consecutive years, with -$116.3 million the latest figure, recorded in Q4 2025.
- Quarterly Other Operating Expenses fell 479.19% year-over-year to -$116.3 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$116.3 million (down 479.19% YoY) and the FY2025 annual result came in at -$43.6 million, up 54.43% from the prior year.
- Other Operating Expenses fell to -$116.3 million in Q4 2025 per MOLN's latest filing, from $1.25 in the prior quarter.
- Over the last five years, Other Operating Expenses for MOLN reached as high as $1.25 in Q3 2025 and fell as low as -$116.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -116.28 Mn |
| Sep 30, 2025 | 1.25 |
| Dec 31, 2024 | -20.08 Mn |